@phdthesis{Reissland2024,
  author    = {Reissland, Michaela},
  title     = {USP10 is a \(de\) \(novo\) tumour-specific regulator of β-Catenin and contributes to cancer stem cell maintenance and tumour progression},
  doi       = {10.25972/OPUS-31957},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-319579},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Colorectal Cancer (CRC) is the third most common cancer in the US. The majority of CRC cases are due to deregulated WNT-signalling pathway. These alterations are mainly caused by mutations in the tumour suppressor gene APC or in CTNNB1, encoding the key effector protein of this pathway, β-Catenin. In canonical WNT-signalling, β-Catenin activates the transcription of several target genes, encoding for proteins involved in proliferation, such as MYC, JUN and NOTCH. Being such a critical regulator of these proto-oncogenes, the stability of β-Catenin is tightly regulated by the Ubiquitin-Proteasome System. Several E3 ligases that ubiquitylate and degrade β-Catenin have been described in the past, but the antagonists, the deubiquitylases, are still unknown. By performing an unbiased siRNA screen, the deubiquitylase USP10 was identified as a de novo positive regulator of β-Catenin stability in CRC derived cells. USP10 has previously been shown in the literature to regulate both mutant and wild type TP53 stability, to deubiquitylate NOTCH1 in endothelial cells and to be involved in the regulation of AMPKα signalling. Overall, however, its role in colorectal tumorigenesis remains controversial. By analysing publicly available protein and gene expression data from colorectal cancer patients, we have shown that USP10 is strongly upregulated or amplified upon transformation and that its expression correlates positively with CTNNB1 expression. In contrast, basal USP10 levels were found in non-transformed tissues, but surprisingly USP10 is upregulated in intestinal stem cells. Endogenous interaction studies in CRC-derived cell lines, with different extend of APCtruncation, revealed an APC-dependent mode of action for both proteins. Furthermore, by utilising CRISPR/Cas9, shRNA-mediated knock-down and overexpression of USP10, we could demonstrate a regulation of β-Catenin stability by USP10 in CRC cell lines. It is widely excepted that 2D cell culture systems do not reflect complexity, architecture and heterogeneity and are therefore not suitable to answer complex biological questions. To overcome this, we established the isolation, cultivation and genetically modification of murine intestinal organoids and utilised this system to study Usp10s role ex vivo. By performing RNA sequencing, dependent on different Usp10 levels, we were able to recapitulate the previous findings and demonstrated Usp10 as important regulator of β-dependent regulation of stem cell homeostasis. Since genetic depletion of USP10 resulted in down-regulation of β-Catenin-dependent transcription, therapeutic intervention of USP10 in colorectal cancer was also investigated. Commercial and newly developed inhibitors were tested for their efficacy against USP10, but failed to significantly inhibit USP10 activity in colorectal cancer cells. To validate the findings from this work also in vivo, development of a novel mouse model for colorectal cancer has begun. By combining CRISPR/Cas9 and classical genetic engineering with viral injection strategies, WT and genetically modified mice could be transformed and, at least in some animals, intestinal lesions were detectable at the microscopic level. The inhibition of USP10, which we could describe as a de novo tumour-specific regulator of β-Catenin, could become a new therapeutic strategy for colorectal cancer patients.},
  subject      = {Biomedizin},
  language  = {en}
}
@phdthesis{SchmittgebWolf2019,
  author    = {Schmitt [geb. Wolf], Karen},
  title     = {Studies on the role of platelet serotonin in platelet function, hemostasis, thrombosis and stroke},
  doi       = {10.25972/OPUS-13471},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134711},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Platelet activation and aggregation are important processes in hemostasis resulting in reduction of blood loss upon vessel wall injury. However, platelet activation can lead to thrombotic events causing myocardial infarction and stroke. A more detailed understanding of the regulation of platelet activation and the subsequent formation of thrombi is essential to prevent thrombosis and ischemic stroke. Cations, platelet surface receptors, cytoskeletal rearrangements, activation of the coagulation cas-cade and intracellular signaling molecules are important in platelet activation and thrombus formation. One such important molecule is serotonin (5 hydroxytryptamin, 5 HT), an indolamine platelet agonist, biochemically derived from tryptophan. 5 HT is secreted from the enterochromaffin cells into the gastrointestinal tract (GI) and blood. Blood borne 5 HT has been proposed to regulate hemostasis by acting as a vaso-constrictor and by triggering platelet signaling through 5 HT2A receptor. Although platelets do not synthetize 5 HT, they take it up from the blood and store it in their dense granules which are secreted upon platelet activation. To identify the molecu-lar composite of the 5 HT uptake system in platelets and elucidate the role of platelet released 5-HT in thrombosis and ischemic stroke, 5 HT transporter knock out mice (5Htt / ) were analyzed in different in vitro and in vivo assays and in a model of is-chemic stroke. In 5Htt / platelets, 5 HT uptake from the blood was completely abol-ished and agonist-induced Ca2+ influx through store operated Ca2+ entry (SOCE), integrin activation, degranulation and aggregation responses to glycoprotein (GP) VI and C type lectin-like receptor 2 (CLEC 2) were reduced. These observed in vitro defects in 5Htt / platelets could be normalized by the addition of exogenous 5 HT. Moreover, reduced 5 HT levels in the plasma, an increased bleeding time and the formation of unstable thrombi were observed ex vivo under flow and in vivo in the abdominal aorta and carotid artery of 5Htt / mice. Surprisingly, in the transient middle cerebral artery occlusion model (tMCAO) of ischemic stroke 5Htt / mice showed near-ly normal infarct volumes and a neurological outcome comparable to control mice. Although secreted platelet 5 HT does not appear to play a crucial role in the devel-opment of reperfusion injury after stroke, it is essential to amplify the second phase of platelet activation through SOCE and thus plays an important role in thrombus stabilization. To further investigate the role of cations, granules and their contents and regulation of integrin activation in the process of thrombus formation, genetically modified mice were analyzed in the different in vivo thrombosis models. Whereas Tph1 / mice (lacking the enzyme responsible for the production of 5 HT in the periphery), Trpm7KI (point mu-tation in the kinase domain of Trpm7 channel, lacking kinase activity) and Unc13d / /Nbeal2 / mice (lacking α granules and the release machinery of dense granules) showed a delayed thrombus formation in vivo, MagT1y/ mice (lacking a specific Mg2+ transporter) displayed a pro thrombotic phenotype in vivo. Trpm7fl/fl Pf4Cre (lacking the non specific Mg2+ channel) and RIAM / mice (lacking a potential linker protein in integrin "inside out" signaling) showed no alterations in thrombus formation upon injury of the vessel wall.},
  subject      = {Serotonin},
  language  = {en}
}
@phdthesis{Kumari2014,
  author    = {Kumari, Geeta},
  title     = {Molecular Characterization of the Induction of Cell Cycle Inhibitor p21 in Response to Inhibition of the Mitotic Kinase Aurora B},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-101327},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {Aurora B ist eine mitotische Kinase, die entscheidende Funktionen in der Zellteilung aus{\"u}bt. Aurora B ist außerdem in einer Vielzahl von Krebsarten mutiert oder {\"u}berexprimiert. Daher ist die Aurora B Kinase ein attraktives Ziel f{\"u}r die Tumortherapie. Gegenw{\"a}rtig werden Aurora B-Inhibitoren zur Behandlung von soliden Tumoren und Leuk{\"a}mien in verschiedenen klinischen Studien getestet. Es fehlen jedoch Informationen, welche molekularen Mechanismen den beschriebenen Ph{\"a}notypen wie Zellzyklusarrest, Aktivierung des Tumorsuppressors p53 und seines Zielgens p21 nach Aurora B-Hemmung zugrunde liegen. Hauptziel dieser Arbeit war es die Mechanismen der p21-Induktion nach Hemmung von Aurora B zu untersuchen. Es konnte gezeigt werden, dass nach Hemmung von Aurora B die p38 MAPK phosphoryliert und somit aktiviert wird. Experimente mit p38-Inhbitoren belegen, dass p38 f{\"u}r die Induktion von p21 und den Zellzyklusarrest ben{\"o}tigt wird. Die Stabilisierung von p53 nach Aurora B-Inhibition und die Rekrutierung von p53 an den p21-Genpromotor erfolgen jedoch unabh{\"a}ngig vom p38-Signalweg. Stattdessen ist p38 f{\"u}r die Anreicherung der elongierenden RNA-Polymerase II in der kodierenden Region des p21-Gens und f{\"u}r die Bildung des p21 mRNA Transkripts notwendig. Diese Daten zeigen, dass p38 transkriptionelle Elongation des p21-Gens nach Aurora B Hemmung f{\"o}rdert. In weiteren Untersuchungen konnte ich zeigen, dass die Aurora B-Hemmung zu einer Dephosphorylierung des Retinoblastoma-Proteins f{\"u}hrt und dadurch eine Abnahme der E2F-abh{\"a}ngigen Transkription bewirkt. Dies l{\"o}st indirekt einen Zellzyklusarrest aus. Weiterhin konnte mit Hilfe von synchronisierten Zellen gezeigt werden, dass p21 nach Durchlaufen einer abnormalen Mitose induziert wird, jedoch nicht nach Aurora B-Hemmung in der Interphase. Interessanterweise werden p38, p53 und p21 schon bei partieller Inhibition von Aurora B aktiviert. Die partielle Inhibition von Aurora B f{\"u}hrt zu chromosomaler Instabilit{\"a}t aber nicht zum Versagen der Zytokinese und zur Bildung polyploider Zellen. Damit korreliert die Aktivierung des p38-p53-p21-Signalweges nicht mit Tetraploidie sondern mit vermehrter Aneuploidie. Die partielle Hemmung von Aurora B f{\"u}hrt außerdem zur vermehrten Entstehung von reaktive Sauerstoffspezies (ROS), welche f{\"u}r die Aktivierung von p38, p21 und f{\"u}r den Zellzyklusarrest ben{\"o}tigt werden. Basierend auf diesen Beobachtungen kann folgendes Modell postuliert werden: Die Hemmung von Aurora B f{\"u}hrt zu Fehlern in der Chromosomenverteilung in der Mitose und damit zu Aneuploidie. Dies f{\"u}hrt zu vermehrter Produktion von ROS, m{\"o}glicherweise durch proteotoxischer Stress, hervorgerufen durch die Imbalanz der Proteinbiosynthese in aneuploiden Zellen. ROS bewirkt eine Aktivierung der p38 MAPK und tr{\"a}gt damit zur Induktion von p21 und dem resultierenden Zellzyklusarrest bei. Aneuploidie, proteotoxischer und oxidativer Stress stellen Schl{\"u}sselmerkmale von Tumorkrankungen dar. Anhand der Ergebnisse dieser Arbeit k{\"o}nnte die Kombination von Aurora B-Hemmstoffen mit Medikamenten, die gezielt aneuploide Zellen angreifen, in Tumorerkrankungen therapeutisch wirksam sein.},
  subject      = {Zellzyklus},
  language  = {en}
}